HAT2 is essential for viability in Leishmania donovani. Key functions include:
Histone H4K10 Acetylation: HAT2 catalyzes acetylation at H4K10, a modification linked to transcriptional activation .
Cell Cycle Regulation: Depletion of HAT2 leads to severe growth defects, impaired survival in host cells, and disruptions in S phase and G2/M progression .
HAT2 modulates gene expression through two regulatory tiers:
Polycistronic Transcription: Most genes are transcribed constitutively from bidirectional promoters at divergent strand switch regions (dSSRs).
Gene-Specific Promoters: Select genes, such as cyclins CYC4 and CYC9, possess dedicated promoters activated in a cell cycle-dependent manner. These promoters are highly sensitive to H4K10 acetylation levels .
Chromatin Sensitivity: Gene-specific promoters (e.g., CYC4 and CYC9) require H4K10 acetylation for activation, unlike dSSR-driven transcription .
Therapeutic Potential: Targeting HAT2 could disrupt parasitic cell cycle machinery, offering a strategy against leishmaniasis .
Experimental Methods: Studies utilized HAT2-heterozygous knockouts, chromatin immunoprecipitation (ChIP), and nuclear run-on assays to map transcriptional dynamics .
Antibody Utility: While no commercial HAT2-specific antibodies are detailed in the provided sources, epigenetic studies often employ antibodies against acetylated histones (e.g., H4acetylK10) to infer HAT activity .
Conservation in Higher Eukaryotes: Whether HAT2 homologs in humans or other organisms share similar regulatory mechanisms remains unexplored.
Structural Characterization: The 3D architecture of HAT2 and its interaction with histone substrates are yet to be resolved.